ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1201

Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica

Patricia Harkins1, Sharon Cowley2, David Kane3 and Richard Conway4, 1St James's Hospital, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Ireland, 3Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, 4Trinity College Dublin, Dublin, Ireland

Meeting: ACR Convergence 2023

Keywords: Aging, Fatigue, mood, Polymyalgia Rheumatica (PMR), quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and overall worse disease outcomes.

The aim of this research was to explore the prevalence of frailty, and its potential associated impact on patient reported outcomes (PRO’s) in a cohort of patients with Polymyalgia Rheumatica (PMR).

Methods: Patients with a diagnosis of PMR (fulfilling the 2012 EULAR/ACR Classification Criteria), who were in clinical remission and on active treatment with glucocorticoids were recruited from two centres. Patients were ≥3 months and ≤12 months from diagnosis.

Frailty was defined by the 5 criteria of the widely validated Fried Phenotypic Frailty Index.

Patient reported outcomes included anxiety, using the Generalised Anxiety Disorder Assessment (GAD-7), mood, using the Patient Health Questionnaire (PHQ-9), fatigue using the Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-F), pain, using the Visual Analogue Scale (VAS) and overall health related quality of life, using the Health Assessment Questionnaire-Disability Index (HAQ-DI). The associations between categorical variables were compared using chi-squared or Fishers exact test where appropriate. The association between continuous variables and categorical variables were assessed using the Kruskal-Wallis test. Correlations were calculated using Pearson’s r. All analyses were conducted using R (R Core Team, 2022). A p-value of < 0.05 was considered as statistically significant.

Results: 51 consecutive patients were recruited, of which 56.9% (n=29) were female. Using the Fried Phenotypic index, 64.7% (n=33) were classified as robust, 27.5% (n=14) as pre-frail, and 7.8% (n=4) as frail. All patients classified as frail were female, and had a statistically significant higher BMI (p=0.040) than those in the robust and pre-frail categories. Compared to robust individuals, those who were frail had statistically significant higher median GAD-7 (p=0.003), PHQ-9 (p=0.001), VAS (p=< 0.001) and HAQ-DI (p< 0.001) scores. FACIT-F scores were also worse in those who were frail versus robust (p=0.001).

Conclusion: Over one third of patients with PMR in this cohort were classified as pre-frail or frail. Increased frailty status was significantly correlated with worse PRO’s, including mood, pain, fatigue and overall quality of life. As frailty is a potentially reversible state, accurately identifying frailty, and implementing appropriate interventions is of utmost importance to ensure improved clinical outcomes in those with PMR.

Supporting image 1

Table 1: Baseline characteristics by frailty classification according to Fried Phenotypic Frailty Index.


Disclosures: P. Harkins: Janssen, 5; S. Cowley: None; D. Kane: None; R. Conway: AbbVie/Abbott, 5, 6, Celltrion, 5, Fresenius Kabi, 6, Galapagos, 6, Janssen, 5, 6, Nordic Pharma, 5, Novartis, 5, UCB, 6, Viatris, 6.

To cite this abstract in AMA style:

Harkins P, Cowley S, Kane D, Conway R. Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/frailty-and-its-impact-on-patient-reported-outcomes-in-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/frailty-and-its-impact-on-patient-reported-outcomes-in-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology